Diadema Partners LP Ultragenyx Pharmaceutical Inc. Put Options Transaction History
Diadema Partners LP
- $328 Billion
- Q2 2025
Put Options
2 transactions
Others Institutions Holding RARE
# of Institutions
360Shares Held
86.9MCall Options Held
3.64MPut Options Held
2.24M-
Vanguard Group Inc Valley Forge, PA10.1MShares$314 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$173 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY4.01MShares$124 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.94MShares$122 Million0.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.89MShares$89.3 Million0.01% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.17B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...